Tosello Valeria, Rompietti Chiara, Papathanassiu Adonia E, Arrigoni Giorgio, Piovan Erich
Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35127 Padua, Italy.
Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Int J Mol Sci. 2024 Dec 18;25(24):13571. doi: 10.3390/ijms252413571.
Increased expression of branched-chain amino acid (BCAA) transaminase 1 (BCAT1) often correlates with tumor aggressiveness and drug resistance in cancer. We have recently reported that BCAT1 was overexpressed in a subgroup of T-cell acute lymphoblastic (T-ALL) samples, especially those with NOTCH1 activating mutations. Interestingly, BCAT1-depleted cells showed pronounced sensitivity to DNA-damaging agents such as etoposide; however, how BCAT1 regulates this sensitivity remains uncertain. Here, we provide further clues on its chemo-sensitizing effect. Indeed, BCAT1 protein regulates the non-homologous end joining (c-NHEJ) DNA repair pathway by physically associating with the KU70/KU80 heterodimer. BCAT1 inhibition during active repair of DNA double-strand breaks (DSBs) led to increased KU70/KU80 acetylation and impaired c-NHEJ repair, a dramatic increase in DSBs, and ultimately cell death. Our results suggest that, in T-ALL, BCAT1 possesses non-metabolic functions that confer a drug resistance mechanism and that targeting BCAT1 activity presents a novel strategy to improve chemotherapy response in T-ALL patients.
支链氨基酸(BCAA)转氨酶1(BCAT1)的表达增加通常与癌症中的肿瘤侵袭性和耐药性相关。我们最近报道,BCAT1在一部分T细胞急性淋巴细胞白血病(T-ALL)样本中过表达,尤其是那些具有NOTCH1激活突变的样本。有趣的是,BCAT1缺失的细胞对依托泊苷等DNA损伤剂表现出明显的敏感性;然而,BCAT1如何调节这种敏感性仍不确定。在这里,我们提供了关于其化学增敏作用的进一步线索。实际上,BCAT1蛋白通过与KU70/KU80异二聚体物理结合来调节非同源末端连接(c-NHEJ)DNA修复途径。在DNA双链断裂(DSB)的主动修复过程中抑制BCAT1会导致KU70/KU80乙酰化增加和c-NHEJ修复受损,DSB显著增加,并最终导致细胞死亡。我们的结果表明,在T-ALL中,BCAT1具有赋予耐药机制的非代谢功能,靶向BCAT1活性为改善T-ALL患者的化疗反应提供了一种新策略。